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Background: Fetal immune tolerance is crucial for pregnancy success. We studied the link between pre-
eclampsia, a severe pregnancy disorder with uncertain pathogenesis, and fetal human leukocyte antigen G
(HLA-G) and other genes regulating maternal immune responses.
Methods: We assessed sex ratios and regulatory HLA-G haplotypes in population cohorts and series of pre-
eclampsia and stillbirth. We studied placental mRNA expression of 136 genes by sequencing and HLA-G and
interferon alpha (IFNa) protein expression by immunohistochemistry.
Findings: We found underrepresentation of males in preeclamptic births, especially those delivered preterm
or small for gestational age. Balancing selection at HLA-G associated with the sex ratio, stillbirth, and pre-
eclampsia. We observed downregulation of HLA-G, its receptors, and many other tolerogenic genes, and
marked upregulation of IFNA1 in preeclamptic placentas.
Interpretation: These findings indicate that an evolutionary trade-off between immune tolerance and protec-
tion against infections at the maternal-fetal interface promotes genetic diversity in fetal HLA-G, thereby
affecting survival, preeclampsia, and sex ratio. We highlight IFNA1 as a potential mediator of preeclampsia
and a target for therapeutic trials.Keywords:
HLA-G
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Preeclampsia
Stillbirth
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Whether human male-to-female sex ratios exhibit appreciable
variation has been a subject of debate in the biological sciences.
Recent large-scale data have confirmed an unbiased sex ratio at con-
ception: equal numbers of X-bearing or Y-bearing sperm fertilize
human eggs. However, the global birth sex ratio of 106 males for
every 100 females, already seen in 20-week fetuses, indicates that
more females are lost in early human pregnancies. In contrast, maledisorder, is a major
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Together, these findings suggest that undetermined fetal sex-specific
mechanisms contribute to human pregnancy success and phenotypic
variation in the sex ratio arises during pregnancy.
In humans, balancing selection at the major histocompatibility
complex (MHC) locus has been proposed to modulate a deficiency of
human leukocyte antigen (HLA) homozygotes through maternal-fetal
interaction, [2] without regard for sex-specificity. Increased HLA sim-
ilarity in couples is associated with recurrent miscarriages, further
supporting the need for the fetus to differ from maternal HLA [3].
Although the exact modifier locus remains unclear, only a limited
pattern of HLA antigens (HLA-C, HLA-E, HLA-F and HLA-G) are
expressed by fetal trophoblasts to prevent rejection by maternal
immune cells [4]. Of these, the non-polymorphic HLA-G is the most
studied due to its trophoblast-restricted expression and multiple iso-
forms inducing both local and systemic immunotolerance during
pregnancy [5].
Tens of studies, with still inconclusive results, have searched for
the link between HLA-G, miscarriages, and the hypertensive preg-
nancy disorder preeclampsia. While reduced HLA-G expression
observed in the preeclamptic placenta is expected to facilitate mater-
nal immune reactions to fetal alloantigens, its role in the pathogene-
sis is not yet clear [611]. Maternal immune maladaptation in
preeclampsia, as one of the major theories, is supported by the shift
from antibody-mediated T-helper 2 (Th2) and regulatory T cells
(Treg) to cell-mediated T-helper 1 (Th1) responses, and by aberrant
natural killer (NK) cell activity [12]. While current pathogenetic mod-
els emphasize the heterogeneity of preeclampsia, rather than immu-
nological mechanisms, [12,13] a possible sex bias in preeclampsia
fetuses should turn attention toward fetal antigens. Remarkably, pre-
eclampsia placentas from male fetuses show more inflammation,
hypoxia, and apoptosis, [14] even if a recent meta-analysis involving
over 3.1 million women failed to show association between male
fetal sex and preeclampsia [15]. In contrast, several cohort and epide-
miological studies have demonstrated an unexplained female pre-
dominance in early preeclampsia [1618].
This study was motivated by the proposed but still disputed sex
bias in preeclamptic births, and particularly, the low male/female
ratio in children of both women and men descending from a proband
with preeclampsia [19]. We hypothesized that male fetal loss might
reflect failure in fetal HLA-G mediated immunotolerance in pre-
eclampsia, stronger maternal immune responses towards male
fetuses, and demonstrate the particular role of HLA-G in maternal-
fetal interaction that affects fetal survival in human pregnancy.2. Materials and methods
Birth registry data. The Finnish Medical Birth Registry, hold by the
Finnish Institute for Health and Welfare in Finland, involves all births
after 22 weeks of gestation and data on maternal and fetal character-
istics. Data spanning 30 years, 1987 to 2016, and including informa-
tion on all live births and stillbirths from 22 gestational weeks or
from 500 g of weight, data on gestational ages at birth, and fetal sex
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(n = 1,790,123). Registry-based diagnoses of mild, severe and unspec-
ified preeclampsia, as recorded during the hospitalization for labor
and delivery, were used to build up the birth cohort with preeclamp-
sia (n = 38,752) and the remaining control population (n = 1,751,371)
without preeclampsia. Registry-based data on previous maternal
miscarriages were available from 36,340 (94%) of preeclamptic births
and were assessed against 1,755,203 births without preeclampsia. In
this dataset, the prevalence of miscarriages before preeclamptic
births was 17.8% (n = 6,469), and 20.3% in the control population.
1000 Genomes data and HLA-G 30UTR haplotype analysis. We used
Ensembl [20] on the reference genome GRCh38 to access 1000
Genomes Project data (1000 Genomes: A Deep Catalog of Human
Genetic Variation, RRID:SCR_006828) [21]. Genotypes for all HLA-G 30
untranslated region (UTR) SNPs were retrieved and automated scripts
were created to build up HLA-G 30UTR haplotypes presenting global
frequencies of >1% (UTR-1 to UTR-7, UTR-10, UTR-18; Fig. S1) [22].
Haplotypes were analysed and the sex ratios (male/female) of indi-
viduals carrying each combination of two haplotypes, diplotypes,
were calculated. Of the total 2,504 individuals (male/female ratio
0.97), only ten individuals (0.4%) carried one or two rare HLA-G 30UTR
haplotypes and were not included in the analyses.
Stillbirth cohort and controls. Samples from the Swedish Biobank
Karolinska involved DNA from stillborn fetuses (n = 277) [23] and
unselected population controls (n = 622). The sex of the individuals
was confirmed by PCR. We used validated primer pairs for the Y chro-
mosomal gene SRY and for the X chromosomal gene ATL1 [24,25]. PCR
assays were run in a volume of 15 mL containing 1 x PCR buffer,
200 mM of dNTPs, 0.1 mM of SRY primers, 0.15 mM of ATL1 primers,
1.0 U of HotStar Taq Plus DNA Polymerase (Qiagen, Valencia, CA), and
50 ng of genomic DNA. Cycling conditions were initial 95 °C for 5 min
to activate the polymerase, followed by 35 cycles of 95 °C for 30 sec,
57.1 °C for 30 sec, and 72 °C for 60 sec, and by the final extension of
72 °C for 5 min. The PCR products were electrophoresed on 2% agarose
gels. For the male-biased sampling of Swedish controls, we did not
study the frequencies of diplotypes and the sex ratios between the
stillborn fetuses (sex ratio 1.18) and the controls (sex ratio 1.21).
FINNPEC series and samples. The Finnish Genetics of Preeclampsia
Consortium (FINNPEC) cohort involves over 1450 women having a
singleton pregnancy with preeclampsia, defined as hypertension and
proteinuria occurring after 20 weeks of gestation. Hypertension was
defined as systolic blood pressure 140 mmHg or diastolic
90 mmHg. Proteinuria was defined as the urinary excretion of
0.3 g protein in a 24 hr specimen, or 0.3 g/L, or two 1+ readings on
a dipstick in a random urine determination without evidence of a uri-
nary tract infection. After the recruitment of a preeclamptic woman, a
woman with a non-preeclamptic pregnancy attending the same clinic
was recruited as a control. Women with chronic hypertension and
superimposed preeclampsia, fulfilling the above-mentioned criteria
of hypertension and proteinuria, were included among preeclamptic
cases. Characteristics of the cohort, classification of mild and severe
preeclampsia, and details on biological samples have been described
[26]. In the FINNPEC cohort, there is only one pregnancy record for
each woman, without repeat pregnancies. We utilized clinical data
on previous pregnancies and offspring sex ratio (male/female). The
numbers of the males and females at birth were tested based on the
number of previous pregnancies (zero to three) among 1,538 off-
spring from preeclamptic births, and separately in 333 small for ges-
tational age (SGA) offspring, in comparison with the 1.79 million
births from the Finnish Birth Registry data. The sex ratio of the whole
FINNPEC series of newborns (n = 1,247) was 1.04, while preeclamptic
newborns showed the ratio of 0.92 and controls the ratio of 1.16.
DNA samples from newborns of preeclamptic (n = 586) and con-
trol (n = 661) pregnancies were analysed. For RNA extraction, we
used 182 deep frozen placental biopsy samples, of which 163 were
included in the final analyses. The biopsies were dissected samples ofvillous tissue under the basal plate [26]. Formalin-fixed and paraffin-
embedded sections from 24 placentas (13 preeclampsia and 11 con-
trols), one sample (n = 3) or two samples (n = 21) from each placenta
taken shortly after cesarian section, were studied by immunohis-
tochemistry. Third trimester maternal serum samples (n = 209; 158
preeclampsia and 51 controls), taken at variable time points during
hospitalization (0 to 31 days before the delivery), and fetal cord
plasma samples (n = 176; 66 preeclampsia and 110 controls), taken
immediately after delivery, were used for ELISA.
Sequencing and HLA-G 30UTR haplotype analysis. Haplotypes of
HLA-G 30UTR were determined by Sanger sequencing among new-
borns of the FINNPEC series and in the stillbirth cohort and controls
using the previously described primers [27]. PCR assays were run in a
volume of 10 mL involving 1 x Phusion HF buffer, 200 mM of each
dNTPs, 0.5mM of each primer, 0.02 U/mL of Phusion DNA-polymerase
(Thermo Fisher Scientific, Waltham, MA), and 20 ng of genomic DNA.
Cycling conditions were 98 °C for 30 sec, followed by 35 cycles of 98 °
C for 10 sec, 64 °C for 30 sec, and 72 °C for 15 sec, and final extension
of 72 °C for 7 min. ExoSAP-IT PCR clean-up was performed according
to manufacturer's instructions (Thermo Fisher Scientific). PCR prod-
ucts were sequenced with the reverse primer, for the detection of the
14 bp deletion/insertion, utilizing the BigDye Terminator v3.1 Cycle
Sequencing Kit and the Applied Biosystems 3730 Genetic Analyzer
(RRID:SCR_018052). HLA-G 30UTR haplotypes were assessed manu-
ally by two readers independently. Haplotypes presenting global fre-
quencies of >1% (UTR-1 to UTR-7, UTR-10, UTR-18) [22] and the sex
ratios (male/female) of individuals carrying each diplotype were
assessed.
RNA extraction. Placental samples, stored snap frozen or in
RNAlater (Thermo Fisher Scientific) in 80 °C, were thawed and
homogenized using the FastPrep-24 5 G Classic Instrument
(2 £ 30 s at 4.5 m/s) and Lysing Matrix D tubes according to man-
ufacturer's instructions (MP Biomedicals, Santa Ana, CA). Samples
were lysed using 600 ml RTL buffer and 6 ml ß-mercaptoethanol
on 20 mg of tissue homogenate, followed by RNA extraction using
the RNeasy Mini Kit according to manufacturer's instructions (Qia-
gen). RNA concentrations were measured (Thermo Scientific Nano-
drop 2000 microvolume spectrophotometer, RRID:SCR_018042)
and samples diluted in 10 ng/ml. The 2100 Bioanalyzer Instrument
(RRID:SCR_018043) (Agilent Technologies, Santa Clara, CA) was
utilized for measurement of RNA integrity (RIN) values. For most
samples, the RIN values ranged from 7 to 8.8, but samples with
the lower range of 4 to 6.9 gave highly comparable results in tar-
geted allele counting by sequencing (TAC-seq) assay testing, and
were included in the final assays. RNA samples were quantified
(Thermo Fisher Qubit 2.0 Fluorometer, RRID:SCR_018095) using
Invitrogen RNA HS Assay Kit (5 to 100 ng) or Invitrogen RNA BR
Assay Kit (20 to 1000 ng) according to manufacturer's instructions
(Thermo Fisher Scientific).
Selection of genes and probe design for TAC-seq. In addition to the
main target HLA-G, we selected several genes known to regulate HLA-
G expression, [5] trophoblast markers, [2830] markers of leukocytes
selected based on an in-house data and FANTOM data (FANTOM DB,
RRID:SCR_002678), [31] members of the B7 family, [32] imprinted
placental genes, [33] preeclampsia-associated genes, [3439] and
housekeeping genes (GAPDH, UBC, TOP1, TBP, SDHA, MRPS18A, and
YWHAZ), in total number of 146 targets. After adding 14 additional
targets to detect seven different isoforms of HLA-G [5], altogether 160
targets were included in probe design (Table S1).
TAC-seq probes were designed to target a 54 bp of coding
sequence near the 50 end of the genes using the software produced
by the researchers of this study (https://hindrek.shinyapps.io/probe_
design/). GC content of the probes was set preferentially at 4555%.
For HLA-G isoforms, the probes were designed manually to cover the
splice sites characteristic of each isoforms and were tested not to
overlap with other HLA I genes by the BLAST program [40].
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using the TAC-seq method [41]. Each target including HLA-G
(n = 146), alternative targets (n = 14) to detect different HLA-G iso-
forms, and ERCC spike-in probes (n = 7; ERCC-00004; 00136; 00108;
00116; 00092; 00095; 00131; Thermo Fisher Scientific) had a pair of
specific oligonucleotides (Table S1). Total-RNA of 2 ml (50 ng/ml) was
mixed with 2 ml denaturation buffer and heated 1 min at 80°C. After
cDNA synthesis in 5 ml, 1 ml of 10 mM TAC-seq probe mixture
was added and incubated 1 hr at 60 °C before adding thermostable
ligase. PCR was carried out in a volume of 40 ml containing
1 £ proofreading HOT FIREPol Blend Master Mix (Solis BioDyne,
Tartu, Estonia) and 250 nM primers. Two-step size-selection was per-
formed to get rid of abundant cDNA (>500 bp) and 80 bp TAC-seq
specific by-product. The 180 bp library was quantified and visualized
on TapeStation High Sensitivity D1000 ScreenTape (Agilent Technol-
ogies). TAC-seq libraries were sequenced with Illumina NextSeq 500
(RRID:SCR_014983) high output 75 cycles kit (Illumina, San Diego,
CA) using 62 bp read-1 and 6 bp index reads.
TAC-seq data processing. The data were deposited in NCBI's Gene
Expression Omnibus (GEO: GSE125460; RRID:SCR_005012) [42]. Raw
data (BCL files) were converted to FASTQ files using the bcl2fastq2
Conversion Software (version 2.20; RRID:SCR_015058), allowing no
mismatches in the index reads. The sequencing quality was evaluated
using MultiQC (version 1.3) [43]. Quality controlled samples were
analysed using the TAC-seq data analysis software (available online
at https://github.com/cchtEE/TAC-seq-data-analysis) as described
[41] allowing up to three mismatches per targeted region of a
sequence. For absolute molecule counts, each read incorporated
4 + 4-bp unique molecular identifier (UMI) sequence [44]. To reduce
the potential over-estimation of molecules due to the accumulated
sequencing errors, only reads that appeared at least twice were
counted as a unique molecule.
Starting from a total of 239 samples including replicates, four
samples were removed as outliers based on their ERCC spike-in mole-
cule counts, and ten samples were excluded due to their low total
molecule counts of <300,000. Before the analyses, 57 replicate sam-
ples were excluded, and four individual samples showing low corre-
lation with other samples were removed as outliers. Finally, one
sample without successful HLA-G 30UTR haplotype analysis was
excluded. As a result, 163 individual samples were retained for fur-
ther analyses: 81 severe preeclampsia, 19 mild preeclampsia, and 63
control samples. Clinical characteristics related to the samples and
subjects are presented in Table S2.
As described above, we started with 167 targets, including seven
spike-in probes, for TAC-seq analysis (Table S1). First, two targets
(IL2, MMP3) were excluded due to low expression (no count in more
than half of the samples). Next, 8 targets (B2M, GAPDH, HSD3B1,
KISS1, PAGE4, PLAC4, SEMA3B, SERPINE2) were removed since they
were considered to reach saturation. We measured HLA-G expression
by 15 different probe pairs and found highly similar patterns of dif-
ferential expression; also for the major soluble isoform (Fig. S2). To
avoid bias for many probes for HLA-G, only one HLA-G target was
included in the final analysis. The probes for this target (target name
HLA-G; Table S1) were designed by the software for the unique
sequence in exon 2, which is present in all isoforms, and those 14
other targets for different HLA-G isoforms were excluded. Finally,
probes for 136 targets retained for the data analysis.
We compared HLA-G mRNA expression levels, adjusted by off-
spring sex, mode of delivery, and gestational age at birth, in pre-
eclampsia and controls by using the Welch’s t-test, and accordingly,
studied expression levels related to different HLA-G 30UTR diplotypes
using linear regression. Moreover, comparison of placental HLA-G
expression with 30UTR haplotypes was performed in two subgroups,
based on the linear regression analysis and residuals of the observed
and predicted sex ratios. The haplotype combinations with positive
residuals were defined as male excess and those with negativeresiduals as female excess. The combination of UTR-3/UTR-5, for
which three males and no females were found, was defined as male
excess but was not shown in the graph. The mean expression levels
of HLA-G mRNA from the unadjusted TAC-seq sequencing output
were compared between the two haplotype groups, male and female
excess, by the Welch’s t-test in preeclamptic (mild and severe) and
control placentas.
Differential expression analysis between control and severe pre-
eclampsia samples was performed with the ‘nbinomWaldTest’
method of an R (version 3.5.0) package DESeq2 (version 1.20.0; RRID:
SCR_015687) [45] using the following housekeeping genes as ‘con-
trolGenes’ for ‘estimateSizeFactors’: UBC, TOP1, TBP, SDHA, MRPS18A,
and YWHAZ. Here, the offspring sex, mode of the delivery (cesarian
section or vaginal birth), gestational age at birth (divided in three
stages: <32 weeks, 3236 weeks, 37 weeks), and disease status
(control, mild preeclampsia, severe preeclampsia) were included
in the design model to correct the potential confounding factors.
IGFBP1, ITGB5, KRT6A, MMP1, MMP9, and TGFB1were regarded as out-
liers due to the Cook’s distance >0.3 and excluded from the differen-
tial expression analysis. A gene was considered as differentially
expressed when the BenjaminiHochberg adjusted P-value was
<0.05.
The expression data were normalized with DESeq2 (RRID:
SCR_015687) and transformed into log2 (x + 1). These values were
then adjusted by the offspring sex, mode of delivery, and gestational
age at birth as described above using the ‘removeBatchEffect’ func-
tion of the LIMMA (version 3.36.5; RRID:SCR_010943) [46].
The plots were generated with ggplot2 (version 3.0.0; RRID:
SCR_014601). The ROC curve (AUC) was calculated using the pROC
package (version 1.13.0) [47]. The statistical significances of the dif-
ferences between two ROC curves were tested by bootstrap method
with 2,000 replicates using the ’roc.test’ function.
STRT RNA-seq library preparation and data processing.We validated
the TAC-seq experiment by STRT RNA-seq by studying RNA samples
from 32 preeclamptic and 32 controls placentas. All these
samples had RIN values of >7. We used 40 ng RNA to make 48-plex
RNA-seq libraries using modified STRT method with UMIs [48,49]
and Globin lock method to deplete the abundant globin transcripts
[50]. Briefly, RNA samples were placed in a 48-well plate in which a
universal primer, template-switching oligos, and a well-specific 6 bp
barcode sequence (for sample identification) were added to each
well [51,52]. The synthesized cDNAs from the samples were then
pooled into one library and amplified by single-primer PCR with the
universal primer sequence. The libraries were sequenced with Illu-
mina NextSeq 500 (RRID:SCR_014983) High Output (75 cycles).
The raw base call (BCL) files were demultiplexed using Picard
tools (version 2.10.10; http://broadinstitute.github.io/picard/) Extrac-
tIlluminaBarcodes and IlluminaBasecallsToSam to generate unaligned
BAM files. These BAM files were converted to FASTQ files with
Picard SamToFastq, and aligned to the human reference genome
hg19, human ribosomal DNA unit (GenBank: U13369), and ERCC
spike-ins (SRM 2374) using HISAT2 (version 2.1.0; RRID:
SCR_015530) [53]. Aligned BAM files were then merged with the
original unaligned BAM files to generate UMI-annotated BAM files
using Picard MergeBamAlignment. These BAM files corresponding
to each sample derived from four lanes were merged using Picard
MergeSamFiles. Finally, potential PCR duplicates were marked by
Picard Markduplicates. The resulting BAM files were processed
with featureCounts (version 1.6.4) [54] to assign the reads to genes
with options “-s 1 largestOverlap ignoreDup primary”. Here,
NCBI RefSeq (hg19) annotations downloaded from UCSC genome
browser (RRID:SCR_005780) with addition of LINC02246
(chr21:16,189,15916,290,989) were used. After removing three
samples with extremely low number of mapped reads, the bias in
read counts between the two libraries was corrected using the
NBGLM-LBC method [55]. Differential expression analysis between
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DESeq2 (RRID:SCR_015687) as described above. The output ‘log2-
FoldChange’ of commonly detected 124 genes was used for the corre-
lation with TAC-seq data. Because the FINNPEC patient consent
doesn’t allow sequencing data storage in public repositories, the
STRT data are not publicly available.
qRT-PCR verification of placental IFNA1 expression. Because IFNA1
expression remained under the detection limit by STRT, we verified
its expression by qRT-PCR. Each RNA sample (32 preeclamptic and 30
controls placentas; 800 ng per sample) used in STRT was reverse
transcribed to cDNA in 20 ml reaction using the RT2 First Strand Kit
(Qiagen) according to manufacturer’s instructions. Real-Time PCR
was performed using RT2 qPCR Primer Assays for IFNA1 (Qiagen;
Cat# PPH01321B-200) and YWHAZ (Qiagen; Cat# PPH01017A-200),
and RT2 SYBR Green Mastermixes. For the low expression of IFNA1,
we used 5 ml of non-diluted cDNA template per reaction for IFNA1
and 2 ml for the housekeeping gene YWHAZ. Real-time PCR was per-
formed in 25 ml reactions according to manufacturer’s instructions
using the Bio-Rad CFX96 qPCR Instrument (Bio-Rad Laboratories, Inc.,
Hercules, CA). The DDCt method was used for data analysis and
Welch’s t-test to compare the relative expression of IFNA1 in pre-
eclamptic (n = 29) versus control (n = 24) placentas with successful
amplification.
We replicated the finding of IFNA1 upregulation in preeclamptic
placentas using an independent publicly available dataset. RNA-seq
data on expression profiles of 21 control and 20 preeclamptic pla-
centas were downloaded from the GEO (RRID:SCR_005012), [42]
under the accession number GSE114691 [56]. Normalization and dif-
ferential expression analysis between these two groups were per-
formed using DESeq2 (RRID:SCR_015687) with default parameters.
Here, genes that had more than 10 read counts in total were
assessed.
Immunohistochemistry and image analysis. We chose the HLA-G
Monoclonal Antibody MEM-G/1 (Thermo Fisher Scientific; Cat#
MA119,219; RRID: AB_1076732), recognizing both membrane-
bound and soluble isoforms of HLA-G, for immunohistochemistry
based on its lacking cross-reactivity with classical HLA I antigens
[57]. The HLA-G antibody was diluted at 1:60 and rabbit monoclonal
antibody to cytokeratin 7 (CK7) (Roche Diagnostics, Rotkreuz, Swit-
zerland; Cat# 7904462) at 1:10. To study cellular source of IFNA1
expression, mouse monoclonal antibody F-7 to interferon a (1/13)
(Santa Cruz Biotechnology, Dallas, TX; Cat# sc-373,757; RRID:
AB_10915749) was used and diluted at 1:100. Ultra-Sensitive ABC
Peroxidase Staining Kit (Thermo Fisher Scientific Cat# 32052) was
used according to the manufacturer’s instructions followed by Metal
Enhanced DAB Substrate Kit (Thermo Fisher Scientific; Cat# 34065).
The anti-HLA-G (n = 45) and anti-CK7 (n = 45) immunostained
slides, in parallel with hematoxylin and eosin stained slides, were
digitized with a whole-slide scanner (Pannoramic 250 FLASH, 3DHIS-
TECH Ltd., Budapest, Hungary) equipped with a 20x objective
(numerical aperture 0.8) and a 1x adapter, and a Global shutter
CMOS camera with 4096 £ 3072 pixels sized 5.5 mm x 5.5 mm (Adi-
mec QUARTZ Q-12A180 camera) resulting in an image in which one
pixel represents an area of 0.243mm x 0.243mm. Images were stored
in a whole slide image format (MRX, 3DHISTECH Ltd., Budapest, Hun-
gary) and further compressed to a wavelet file format (Enhanced
Compressed Wavelet, ECW, ER Mapper, Intergraph, Atlanta, GA) with
a target compression ratio of 1:10. The compressed virtual slides
were uploaded to a whole-slide image management server (Aiforia
Technologies Oy, Helsinki, Finland).
Two convolutional neural network-based algorithms were trained
using a cloud-based software (Aiforia Create, Aiforia Technologies Oy,
Helsinki, Finland) for image analysis to separately identify anti-CK7
and anti-HLA-G immunostained tissue areas. Each algorithm consists
of two algorithms in sequence, the first segmenting the extravillous
tissue areas and the second algorithm to identify trophoblasts thatexhibit a strong HLA-G expression or a strong CK7 expression respec-
tively. The network for the detection of anti-HLA-G stained tissue
areas was trained with 588 image annotations corresponding to an
area of 0.0066 mm2 and 0.001 mm2 extravillous tissue. The algorithm
for detecting anti-CK7 immunostained tissue areas was trained with
193 image annotations corresponding to an area of 0.11 mm2 and 22
mm2 extravillous tissue. We used a feature size of 15 mm for training
the areas with strong HLA-G expression and a feature size of 10 mm
for training the algorithm for detection of anti-CK7 stained tissue
areas. The augmentation parameters for detection of anti-HLA-G
immunostaining were 0°360° rotation, §20% aspect ratio change,
§10% shear distortion, §20% brightness and §20% contrast change
and augmentation parameters for the detection of CK7 expression
were 0°360° rotation, §5% aspect ratio change, §50% shear distor-
tion, §5% brightness and §5% contrast change. All data were flipped
both vertically and horizontally. The algorithm performances were
validated against manual annotations done by one of the researchers
(NL).
HLA-G/CK7 protein ratios were received from the image analysis.
For the placentas with two biopsies, mean ratios were calculated and
used in the analyses. HLA-G/CK7 protein ratios were plotted against
HLA-G/CK7 mRNA ratios, which were calculated for each placenta
from the TAC-seq data, after adjustment the expression data by off-
spring sex, mode of delivery, and gestational age at birth (<32,
3236, 37 weeks) as described. Spearman correlation coefficient
was calculated to study the relationship between HLA-G/CK7 mRNA
and protein expression. HLA-G/CK7 protein ratios were studied in
relation to the gestational weeks at delivery. Comparison of nonlinear
fits in preeclamptic and controls pregnancies was performed. We fur-
ther studied the differences in protein expression between the two
sexes in preeclampsia and control offspring by using the Student’s t-
test.
ELISA. Human IFNa ELISA Kit (Sigma-Aldrich, Merck, Darmstadt,
Germany; Cat# RAB0541) was used according to the manufacturer’s
instruction to detect IFNa1/13 in third trimester maternal serum
samples (n = 209; 158 preeclampsia and 51 controls), taken at vari-
able time points during hospitalization (0 to 31 days before the deliv-
ery), and fetal cord plasma samples (n = 176; 66 preeclampsia and
110 controls), taken immediately after delivery. We first tested the
mean absorbance of two duplicates from a total of 32 samples, and
found the average coefficient of variance (cv) of 6%, which was below
the intra-assay cv of <12% reported by the manufacturer. For the lim-
ited availability of samples, the final experiments were run without
duplicates, using 100 ml of each sample, SYNERGY H1 Microplate
reader, and the Gen5 Software (BioTek Instruments, Winooski, VT).
Standard curve was defined according to the kit’s instructions and
standard dilutions. Values were converted to ng/mL by reference to a
standard curve which was generated in parallel with the test samples
in each run.
Maternal and fetal IFNa concentrations were compared by the
Mann-Whitney U test, and studied in relation to the disease status by
the Chi-Square test in preeclamptic vs. non-preeclamptic pregnan-
cies. Levels of maternal blood pressure were compared between the
subgroups with IFNa concentrations below and at/above the median
value (Mann-Whitney U test).
Statistics. Statistical analyses were carried out using GraphPad
Prism software, version 8.3.0 (GraphPad Software, San Diego, CA),
unless otherwise stated. Two-sided P values of 0.05 or less were con-
sidered statistically significant.
Chi-Square test was used to compare the proportions of males and
females at birth in preeclamptic and control pregnancies, with and
without history of miscarriages, and Spearman correlation coeffi-
cients to study the relationship between the sex ratio and gestational
ages at birth.
The sex ratios were further analysed using a generalized linear
model (GLM; events-trials, binomial distribution and logit link
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For the 1000 Genomes dataset, the model included the allele 1, allele
2, location (African vs. Non-African populations) and haplotype fre-
quency as main effects, and the interaction of allele 1 and allele 2, as
well as the interaction of location and haplotype frequency. For the
FINNPEC dataset, the final model included the allele 1, allele 2, haplo-
type frequency and maternal condition (preeclampsia or control) as
main effects, and the interaction of allele 1 and allele 2. In these mod-
els, the dependent variable (sex ratio) was analysed as the number of
males out of total offspring.
The numbers of homozygous and heterozygous individuals for
HLA-G 30UTR and the associated ORs and 95% CIs were calculated by
Chi-Square test. The numbers of the observed HLA-G 30UTR haplo-
types were compared between stillborn fetuses and controls, and in
preeclampsia offspring and controls, using Chi-Square test and com-
paring the haplotypes one by one against all other haplotypes.
RNA and protein expression analyses and statistical methods are
detailed in the corresponding sections describing the methods for
TAC-seq, STRT RNA-seq, RT-qPCR, immunohistochemistry, and ELISA.
Ethics Statement and Study approval. Written informed consent
was received from all participants in the FINNPEC cohort [26]. Sam-
ples for the stillbirth cohort were from the Biobank Karolinska. All
methods were carried out in accordance with protocols approved by
the participating institutions (Helsinki University Central Hospital
149/E0/07; Karolinska Institutet 2008/67031/2 and 2015/170431/
1) and in agreement with the Declaration of Helsinki.
3. Results
3.1. Male fetuses are underrepresented in preeclamptic births
We examined birth sex ratios (male/female) in a Finnish popula-
tion cohort of 1.79 million live and stillbirths. This cohort included
38,752 preeclamptic births (2.2%). The sex ratio was 1.02 in pre-
eclamptic and 1.05 in non-preeclamptic births (OR 0.97, 95% CI: 0.95
to 0.99; P = 0.006; Chi-Square test), and the earlier the gestational
age at birth, the lower the number of male offspring in preeclampsia
(Spearman correlation coefficient, 0.80; P = 0.007) (Fig. 1a). The sex
bias was in striking agreement with Norwegian data on 1.82 million
births and 44,000 preeclamptic pregnancies, [16] and with others
[18]. Together with the data on unbiased human sex ratio at concep-
tion [1] and familial association of preeclampsia and miscarriages,
[58] our results suggested male fetuses being lost before the onset of
early preeclampsia, or linked to a higher risk of term disease, or both.
In the preeclampsia cohort (n = 1,538), the higher number of pre-
vious pregnancies was associated with reduced number of male off-
spring in preeclamptic women, especially in those delivered small for
gestational age (Fig. 1b). This deficiency of male offspring was not
present in first pregnancies complicated with preeclampsia. The defi-
ciency of males in multiparous preeclamptic births could have two
explanations: (1) the 'missing males' are in the non-preeclamptic
birth category (maleness is protective) or (2) males in potentially pre-
eclamptic pregnancies are lost before birth. To provide evidence of
preferential loss of males, we studied population-level data on
women with one or more miscarriages and found the reduced sex
ratio of 0.98 in consecutive preeclamptic (n = 6,469) compared with
1.04 in non-preeclamptic births (n = 355,683) (OR 0.95, 95% CI:
0.900.99; P = 0.03; Chi-Square test). Moreover, we studied a Swed-
ish stillbirth cohort (n = 277), which showed increased intrauterine
loss of male fetuses with the sex ratio of 1.18, being in agreement
with earlier findings. [1] Altogether, these findings of sex-ratio distor-
tion propose that maternal immune responses to the male-specific
Y chromosomal histocompatibility (H-Y) antigen, [59] present on
fetal cells or microchimeric cells retained in the mother's body
from the previous pregnancy, [60] contribute to fetal survival and
preeclampsia.3.2. Fetal HLA-G 30UTR modulates human sex ratio
HLA-G downregulation is linked to its 30 untranslated regulatory
region (30UTR) (Fig. S1), which is associated with distinct full-length
haplotypes, and modulates mRNA stability and decay, microRNA tar-
geting, and splicing [5,22,61,62]. To uncover the link between HLA-G
and the sex ratio, we studied 30UTR haplotype pairs, diplotypes, rep-
resenting functional units. Rare diplotypes showed opposite patterns
of sex ratios in preeclampsia offspring (Fig. 1c) and stillborn fetuses
(Fig. 1d), and HLA-G diplotype was the main determinant of the birth
sex bias between preeclampsia and control offspring (Fig. 1e). Simi-
larly, HLA-G haplotypes were associated with the bias in the sex ratio
between African versus Non-African populations in the 1000
Genomes data (Fig. 1f, 1g and 1h), the African populations having the
highest global prevalence of preeclampsia [63]. Altogether, rare dip-
lotypes showed more variation in the sex ratio than the common
ones, which were close to the balance of 1.0. These results indicate
balancing selection and negative frequency-dependence of allelic fit-
ness (rare allele advantage), meaning that rare alleles are favored and
the fitness of each allele decreases as its frequency increases [64].
We further tested segregation of individuals homozygous for HLA-
G 30UTR. Decreased HLA-G homozygosity was observed in African
(18.3% homozygous) versus Non-African populations (24.4%), and in
the stillbirth cohort (18.4%) versus population controls (25.7%), with-
out sex-specific differences. Preeclampsia (26.8%) versus control off-
spring (26.3%) showed no differences in the overall homozygosity.
However, homozygous males (31.7%; 35.2% in first pregnancies) ver-
sus females (22.3%; 21.4% in first pregnancies) were overrepresented
in preeclamptic births (Fig. 2). These findings provide more support
for balancing selection and are suggestive of heterozygote advantage.
This is a special case of negative frequency-dependent selection and
means that a greater proportion of the rarer allele than the more
common allele is present in advantaged heterozygotes [2,65].3.3. HLA-G 30UTR shows association with preeclampsia and stillbirth
The two major HLA-G 30UTR haplotypes, UTR-1 and UTR-2, differ
for five polymorphic sites, mostly associate with the same HLA-G pro-
tein, and have global frequencies of 2030% each [22]. Of them, the
evolutionarily most recent UTR-1 showed reduced frequency
(P = 0.01; OR 0.77, 95% CI: 0.630.94; Chi-Square test) and the ances-
tral haplotype UTR-2 [66] increased frequency (P = 0.01; OR 1.34, 95%
CI: 1.071.69; Chi-Square test) in preeclampsia versus control off-
spring in first-time mothers. For UTR-2, the association remained
when offspring from later pregnancies were included (P = 0.04; OR
1.22, 95% CI: 1.011.47; Chi-Square test) (Table S3). The observed
ORs are considered good approximations of the risk ratio, because of
the low preeclampsia rate of 2.1% during the preeclampsia series col-
lection. The opposite effects of UTR-1 and UTR-2 on preeclampsia
risk in first pregnancies support the advantage of divergent alleles
and heterozygosity. Moreover, previous studies link UTR-2 to low
expression, immune-mediated disorders, and pregnancy complica-
tions, and UTR-1 to high HLA-G expression and increased mRNA sta-
bility [5,11,67]. In line with this, the stillbirth cohort showed a
similar but more significant protective effect of UTR-1 (P = 0.0001;
OR 0.65, 95% CI: 0.530.81; Chi-Square test). Conversely, UTR-5 was
detected as a risk haplotype for stillbirth (P = 0.03; OR 1.72, 95% CI:
1.062.79; Chi-Square test) (Table S4). UTR-5 is considered the oldest
of all haplotypes and is closest to orthologous sequences in non-
human primates [66]. We further confirmed that the 14 bp insertion
polymorphism, previously implicated in pregnancy complications
and present in haplotypes UTR-2, 5 and 7, [11,22] showed a mod-
est association with both stillbirths (P = 0.04; OR 1.24, 95% CI:
1.011.52) and preeclampsia (P = 0.03; OR 1.21, 95% CI: 1.02 to 1.44;
Chi-Square test).
Fig. 1. Biased birth-sex ratio in preeclampsia is associated with balancing selection of HLA-G 30UTR diplotypes. (a) Population-level birth sex ratios in preeclampsia and control
pregnancies. Preeclamptic births after 41 weeks were rare (n = 512) and the sex ratio of 0.99 comparable with that of the controls (data not shown). (b) The number of previous
pregnancies and associated birth sex ratios in the population, in the cohort of preeclamptic pregnancies, and in the subgroup of preeclamptic pregnancies with small for gestational
age (SGA) offspring. Numbers of individuals are represented in the bars and P values (Chi-Square test) for birth sex differences above the graphs (a and b); dashed lines indicate the
population birth sex ratio of 1.05 and n.s. denotes non-significant. The distribution of HLA-G 30UTR diplotypes (e.g. 1/2 denoting UTR-1/UTR-2) and the associated birth sex ratios in
(c) preeclampsia, (d) stillborn fetuses, and (e) control offspring. Horizontal lines indicate the balanced sex ratio of 1.0. The preeclampsia cohort (c and e) indicates that the HLA-
G diplotype is the main determinant of the bias in the birth sex ratio (GLM; allele 1: F5,21=0.44, P = 0.82; allele 2: F7,21=3.51, P = 0.01; allele 1 by allele 2 interaction: F13,21=9.15,
P<0.001; haplotype frequency: F1,21=0.67, P = 0.42; maternal condition: F1,21=3.58, P = 0.07). (f) The 1000 Genomes dataset indicates that the haplotype, haplotype frequency and
geographic location all explain the bias in the sex ratio between (g) African and (h) Non-African individuals (GLM; allele 1: F7,24=41.63, P<0.001; allele 2: F8,24=8.23, P<0.001; allele
1 by allele 2 interaction: F21,24=2.27, P = 0.028; location: F1,24=6.28, P = 0.02; haplotype frequency: F1,24=7.87, P = 0.01; location by haplotype frequency interaction: F1,24=8.47,
P = 0.008).
Fig. 2. Patterns of HLA-G 30UTR homozygosity support balancing selection. The
odds ratios (dots) and 95% confidence intervals (whiskers) for homozygous versus het-
erozygous individuals for HLA-G 30UTR in African versus Non-African populations, still-
born fetuses versus populations controls, and in preeclampsia versus control offspring.
The comparisons between homozygous and heterozygous males versus females were
performed in African individuals, stillborn fetuses, and in preeclampsia offspring. Only
P values <0.05 are shown (Chi-Square test).
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preeclamptic placentas
To test the hypothesis of maternal immunoreactivity as the mech-
anism of fetal selection, we studied placental samples (n = 163) for
mRNA expression of 136 HLA-G related, placenta-specific, and pre-
eclampsia-associated genes (Table S1) using the highly quantitative
TAC-seq method [41] and validated by STRT RNA sequencing
(Fig. S3). HLA-G expression, measured by 15 different probe pairs,
showed consistent downregulation in preeclamptic placentas. HLA-G
30UTR diplotypes were associated with differential HLA-G expression
in controls but HLA-G expression was always low in preeclamptic pla-
centas, irrespective of the haplotype combinations (Fig. 3a and
Fig. S2). Although UTR-1/UTR-1 was among those with the highest
and UTR-2/UTR-2 among those with the lowest HLA-G expression in
non-preeclamptic placentas, differences between the individual hap-
lotypes were non-significant due to the small number of samples. To
support the association between HLA-G 30UTR, preeclampsia, and
fetal sex, the diplotypes producing more males were associated with
higher placental HLA-G mRNA expression (Fig. 3b and 3c). This find-
ing suggested that sex-related segregation of HLA-G haplotypes is
associated with differential HLA-G expression levels. Similarly, we
observed higher HLA-G protein expression in preeclamptic placentas
Fig. 3. HLA-G downregulation in preeclamptic placentas. (a) HLA-GmRNA levels and 30UTR diplotypes in preeclamptic and control placentas (n = 163; P = 1.63 £ 104; Welch's t-
test); comparisons between diplotypes remained non-significant. The number of samples are shown above the graph and linear regression lines separately for controls (blue) and
preeclampsia (red). Haplotypes are arranged based on the highest to the lowest expression observed in the control placentas. (b) Linear regression summarizes HLA-G diplotypes
with positive residuals, defined as male excess, and with negative residuals, defined as female excess, in the cohort of preeclamptic and control offspring (n = 1,247). Analysed based
on this classification, (c) demonstrates higher placental (n = 163) HLA-G mRNA expression in association with diplotypes showing male excess (Welch’s t-test). (d) HLA-G/CK7 pro-
tein ratios, and two regression lines with significantly different slopes (P = 0.02), demonstrate HLA-G protein expression in preeclamptic (n = 13; red) and control placentas (n = 11;
blue). HLA-G protein expression was lower in female (n = 7) compared with male offspring (n = 6) in preeclampsia (PE) (Student’s t-test), but no sex-related differences arose in con-
trols. Horizontal line indicates the mean of all samples. (e) Spearman correlation (r) visualized as scatterplot shows HLA-G/CK7 protein and mRNA expression in 24 placentas. RNA
expression levels are shown adjusted by offspring sex, mode of delivery and gestational age at birth; only panel c shows unadjusted data. (f) HLA-G immunoreactivity (marked in
red by the image analysis) on extravillous trophoblasts in the representative preeclamptic (PE) placenta (female born at 29 weeks; HLA-G UTR-2/UTR-4) with 2% and the control
(Ctrl) placenta (female born at 32 weeks; HLA-G UTR-1/UTR-2) with 13% HLA-G positive trophoblasts (scale bars, 500 mm). For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.))
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firmed the correlation between HLA-G/CK7 mRNA and protein
expression (Fig. 3e and 3f). Collectively, these findings supported
sex-related differences and downregulation of HLA-G in preeclamptic
placentas independently of trophoblast count, as defined by CK7
expression.
Altogether 36 genes were differentially expressed between severe
preeclampsia (n = 81) and controls (n = 63); 8 upregulated and 28
downregulated (Fig. 4a; Table S5). Collectively, we found downregu-
lation of HLA-G and other markers for differentiated trophoblasts
(IL2RB, MMP2, SPRR2G, LAIR2, TGFB2), [29] HLA-G receptors (LILRB1
and LILRB2), [5] immune escape molecules of the B7 family
(PDCD1LG2/B7-DC/CD273 and CD276/B7-H3), [32] Th2 cytokine IL10,Fig. 4. Downregulation of tolerogenic genes and upregulation of IFNA1 in preeclamptic p
cental genes (Padj<0.05; DESeq2 Wald test) in severe preeclampsia (n = 81) versus controls (
fold change. (b) ROC curves show a significantly higher mean (§SE) area under the curve f
Expression levels were adjusted by offspring sex, mode of delivery, and gestational age at
referred to the web version of this article.[68] and many leukocyte markers (CD300E, MS4A7, AQP9, GNLY) in
preeclamptic placentas. We found no evidence that other immune-
related genes such as IDO, HLA-E or HLA-F would compensate HLA-G
downregulation in preeclampsia. Altogether, we observed an overall
downregulation of tolerogenic genes in preeclamptic compared with
control placentas.
Fms-like tyrosine kinase 1 (FLT1), a major driver of maternal hyper-
tension in preeclampsia, [69] showed the second highest upregula-
tion in preeclamptic placentas. Notably, a major IFN subtype alpha-1
(IFNA1), [70] a cytokine modulating innate and adaptive immune
responses, [71] was the most upregulated gene in preeclampsia
(Fig. 4a), while interferon beta and gamma showed no differences.
We further confirmed upregulation of IFNA1 in preeclampsia by qRT-lacentas. (a) Volcano plot of downregulated (blue dots) and upregulated (red dots) pla-
n = 63). Horizontal dashed line indicates Padj=0.05 and vertical dotted line indicates no
or HLA-G and IFNA1 as predictors of preeclampsia when compared with FLT1 and PGF.
birth. For interpretation of the references to color in this figure legend, the reader is
Fig. 5. HLA-G 30UTR haplotypes show asymmetry for FLT1 expression. Shown are expression levels of HLA-G, IFNA1 and FLT1 divided based on the HLA-G 30UTR haplotypes tar-
geted by selection. (a) The samples (n = 95) with the most common diplotypes (UTR-1/UTR-4, UTR-1/UTR-2, UTR-1/UTR-1, and UTR-2/UTR-4) and the samples (n = 68) with rare dip-
lotypes (all others). (b) The heterozygous (n = 120) samples and the homozygous samples (n = 43) for HLA-G 30UTR. Expression levels were adjusted by offspring sex, mode of
delivery, and gestational age at birth. P values were calculated by the Welch’s t-test.
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ing dataset (Fig. S5) [56]. We studied cellular source of IFNA1 and
detected protein expression in fetal trophoblasts (Fig. S6). We further
observed that fetal, but not maternal, circulating IFNa levels were
associated with maternal hypertension (Fig. S7). These findings are in
line with the absence of transplacental transfer of IFNa [72] and sup-
port the fetal compartment in IFNa production.
In our TAC-seq dataset, placental expression of HLA-G and IFNA1
distinguished preeclamptic placentas better than expression of the
current biomarkers FLT1 and placental growth factor (PGF) (Fig. 4b)
[73]. We further studied gene expression patterns related to the HLA-
G regulatory haplotypes, and found that, FLT1 was the main measure
that differed between common versus rare, and homozygous versus
heterozygous, placentas with respect to control and preeclampsia
(Fig. 5).
4. Discussion
Our study provides evidence that failure in fetal HLA-G mediated
immune escape is associated with stillbirth and preeclampsia, and
that intriguingly, the birth sex ratio in these pregnancy complications
reflects the action of this mechanism in vivo. We link regulatory HLA-
G haplotypes to the offspring sex and pregnancy complications by
the two major mechanisms of balancing selection at the MHC locus:
negative frequency-dependent selection (rare allele advantage) and
heterozygote advantage [64,65]. While negative frequency-depen-
dent selection has been proposed to keep sex ratios balanced, [74]
there is very limited earlier evidence for a genetic link to sex ratio.
Thus, to our knowledge, we present the first evidence in any species
of a gene modulating the sex ratio and suggest that fetal HLA-G is a
sexually antagonistic locus determining maternal-fetal interaction
and human pregnancy success. Furthermore, we provide evidence
that balancing selection is acting on contemporary human popula-
tions and contributes to human pregnancy complications. Moreover,
our findings add significant novel data to support the hypothesized
role of aberrant IFN signaling in pregnancy complications, [75] as
shown in mouse Zika virus infection, [76] but with limited previous
data on human pregnancies.Although we studied large cohorts, the heterogeneity of pre-
eclampsia and challenges in the establishment of explicit diagnostic
criteria remain a matter of speculation. Similarly, the 2.2% rate of pre-
eclampsia in the Finnish birth registry data is close to the lowest
global estimate of 2%, [13] but due to the general and equal access to
maternal care with globally low infant mortality may miss only a few
cases. Our registry data involved only births after 22 weeks of gesta-
tion, thus providing only indirect evidence of the association between
male fetal loss and the biased birth sex ratio in preeclampsia. How-
ever, our results are broadly compatible with the earlier findings of
female-biased birth sex ratio in early preeclampsia [1618] and with
greater losses of male conceptions before female live births with pre-
eclampsia or low birth weight, as demonstrated in couples with
recurrent miscarriages [77,78]. Furthermore, both clinical cohorts
supported the association between HLA-G haplotypes, the sex ratio,
and pregnancy complications. That even the unselected global 1000
Genomes populations showed association between HLA-G haplotype
segregation and the sex ratio, further supports the robustness of
these results.
Our results show underrepresentation of male offspring in pre-
eclamptic births, especially those delivered preterm or small for ges-
tational age. This finding supports the vulnerability of male fetuses to
maternal inflammation [79] and late miscarriages and stillbirths [1].
Because there was no sex-ratio distortion in first pregnancies, but the
deficiency of males was present only in multiparous births, our find-
ings may reflect a different etiology of preeclampsia in first and sub-
sequent pregnancies. Our results show, however, the highest risk of
preeclampsia in first pregnancies with a male fetus homozygous for
HLA-G 30UTR, thus supporting the association between male fetal sex
and preeclampsia also in first-time mothers. Furthermore, our find-
ings indicate that fetal HLA-G might be the locus mediating a defi-
ciency of HLA homozygotes through maternal-fetal interaction [2]
and explaining HLA similarity in couples with recurrent miscarriages
[3]. In contrast, heterozygote advantage looks apparent for African
populations, but heterozygosity also shows an association with still-
birth in the Swedish series. This suggests that heterozygote advan-
tage might be related to special circumstances, such as resistance to
infectious diseases as proposed for the MHC locus [65]. Thereby,
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interactions and the suggested association between viral infections
and preeclampsia [80,81].
Our results strengthen the earlier findings of HLA-G downregula-
tion in preeclamptic placentas [68]. We studied a large number of
samples and HLA-G/CK7 ratios to demonstrate that HLA-G mRNA and
protein downregulation in the preeclamptic placentas was not
explained by the lower number of trophoblasts in the samples.
Although our dataset was small to show significant differences
between specific HLA-G 30UTR haplotypes and expression levels, we
found an overall trend and added novel data by demonstrating the
association between HLA-G mRNA and protein expression and fetal
sex. Additionally, we showed downregulation of HLA-G receptors,
such as LILRB1 linked to lower expression in first pregnancies, [82]
and many other tolerogenic genes in preeclamptic placentas. Further-
more, our results suggest that IFNa signaling might drive loss of fetal
immunotolerance in preeclampsia, as implicated in systemic lupus
erythematosus (SLE), [83] in tumor rejection, [84] and in solid organ
transplantation [85]. To support this, increased IFNa/b signaling is
associated with preeclampsia in SLE women, [86] inflammation-
driven preterm birth in mice and humans, [87,88] and in a pathway
crosstalk analysis of preeclampsia [89]. While viruses and bacteria
are the main triggers of IFNa/b production but rarely present in the
human placenta, [90,91] even fetal DNA immune complexes alone,
excessively released from damaged cells of the preeclamptic pla-
centa, [92,93] may activate the autophagy pathway and promote
prolonged IFNa production [83,94]. Importantly, hydroxychloro-
quine (HCQ) reduces IFNa production and preeclampsia in SLE
women, [9597] improves endothelial function in an in vitro model
of preeclampsia [98] and in SLE mice, [99] as well as prevents placen-
tal inflammation and fetal loss in mice [100,101]. Therefore, the
mechanisms presented here encourage targeting IFNa signaling in
clinical trials and testing whether HCQ has general therapeutic effects
in preeclampsia.
This study indicates that HLA-G heterozygosity, as a determi-
nant of fetal survival, might be associated with enhanced FLT1
responses. Remarkably, previous studies link overexpression of
FLT1 to fetal self-defense against decidual VEGF signaling [102].
Supporting fetal defense and maternal-fetal conflict, high fetal
FLT1 levels confer resistance against placental malaria and fetal
loss [103] and maternal (decidual) macrophages express VEGF in
placental malaria [104]. Considerably, maternal hypertension and
elevated sFLT1 levels are not specific to preeclampsia but arise in
first-time mothers with placental malaria [104]. Moreover, low
HLA-G expression emerges in preeclamptic placentas, but also in
trophoblasts infected by Plasmodium falciparum [105] and some
viruses (CMV, HSV) [106108]. In further support of shared mech-
anisms, placental malaria and preeclampsia show high rates and
seasonal co-occurrence in Africa,[109] where both the HLA-G low-
expressing “null allele” and high-expressing FLT1 alleles are under
positive selection, [103,110] and the frequency and sex ratios asso-
ciated with HLA-G 30UTR haplotypes differ from other populations
as shown in this study. Furthermore, the African “null allele” is
mostly associated with UTR-2, [22] the haplotype showing an
increased risk of preeclampsia in this study. Thus, we suggest that
low HLA-G expression may be advantageous in pathogen-rich
environments to mount protective maternal immune responses,
while concurrently detrimental, causing unfavorable maternal
anti-fetal immune reactions, fetal loss, and preeclampsia. In agree-
ment with this scenario, ancestral fetal HLA-G haplotypes showed
associations with preeclampsia and stillbirths in our series,
thereby supporting their disadvantage in modern environments.
Furthermore, high HLA-G expression is associated with higher
implantation rates [111] and uneventful pregnancies as presented
here, but might confer an increased risk of offspring to malaria
and other infections [112,113].Collectively, our results suggest that balancing selection at fetal
HLA-G locus modulates fetal survival, preeclampsia and birth sex
ratio. We propose that preeclampsia involves coevolutionarily
balanced mechanisms: downregulation of fetal HLA-G mediated
immunotolerance, upregulation of maternal immune responses as
reflected by male fetal loss, and upregulation of fetal self defense
mechanisms such as overexpression of FLT1 and IFNA1. Although
these mechanisms may have evolved to protect both the fetus and
the mother from invading pathogens, they increase the risk of mater-
nal immune attack against the fetus, fetal loss, and preeclampsia. We
suggest that this coevolutionary balancing explains the highest inci-
dence of preeclampsia in sub-Saharan Africa and promotes genetic
diversity in fetal HLA-G. Future studies should test whether other
mechanisms, such as the lack of alleles in the fetus but their presence
in the mother, [114,115] might modulate fetal selection and contrib-
ute to human pregnancy complications. While HLA-G shows physio-
logical expression almost uniquely in trophoblasts, its high
expression that benefits the viability of fetuses during pregnancy
may trade-off with HLA-G neoexpression, promoting immune eva-
sion of viruses and malaria as well as tumors later in life [5,116].
Therefore, the benefit of differential HLA-G expression may be depen-
dent on the pathogen load and the tissue of expression, providing a
role for balancing selection on immune-related traits beyond preg-
nancy in human evolution.
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